Get the Stockscreener App
40.51
0.00%
-0.0582
Mirum Pharmaceuticals Inc stock is traded at $40.51, with a volume of 100.41K.
It is down -0.00% in the last 24 hours and up +3.03% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$40.45
Open:
$39.69
24h Volume:
100.41K
Relative Volume:
0.27
Market Cap:
$1.94B
Revenue:
$264.38M
Net Income/Loss:
$-109.16M
P/E Ratio:
-9.4297
EPS:
-4.2958
Net Cash Flow:
$-39.22M
1W Performance:
+3.56%
1M Performance:
+3.03%
6M Performance:
+56.54%
1Y Performance:
+34.83%
1-Day Range:
$38.16
$41.00
1-Week Range:
$38.16
$41.15
52-Week Range:
$23.14
$45.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
AlphaCentric Advisors LLC Decreases Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - StockTitan
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
How to Take Advantage of moves in (MIRM) - Stock Traders Daily
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Leerink Partners Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $49.00 - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $49.00 at Leerink Partners - MarketBeat
Mirum PharmaEyeing 50% Annual Growth In 2023 - RTTNews
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
(MIRM) Trading Advice - Stock Traders Daily
H.C. Wainwright maintains Buy rating on Mirum shares as enrollment for key study continues - Investing.com Canada
Analyst Expectations For Mirum Pharmaceuticals's Future - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Given "Buy" Rating at HC Wainwright - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA grants breakthrough status to Mirum's PBC drug By Investing.com - Investing.com Canada
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - BioSpace
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation from FDA - MarketWatch
Millennium Management LLC Has $9.08 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Abacus & Mirum Partner For The Commercialization Of LIVMARLI In Nordic Markets - Contract Pharma
Cantor Fitzgerald Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight Recommendation - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Clearbridge Investments LLC - MarketBeat
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish (MIRM) - Seeking Alpha
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Squarepoint Ops LLC - MarketBeat
Alagille Syndrome Market Forecasted to Surge in Coming Years, - openPR
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading 5.9% Higher - MarketBeat
(MIRM) Investment Report - Stock Traders Daily
Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $56.27 - MarketBeat
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Axa S.A. Sells 167,794 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Profund Advisors LLC Has $445,000 Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
XTX Topco Ltd Invests $521,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Micron Technology Inc. stock rises Tuesday, outperforms market - MarketWatch
Farallon Capital Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Market Insight: Merus N.V (MRUS)’s Notable Drop, Closing at 47.77 - The Dwinnex
Great Point Partners LLC Increases Stake in Merus (NASDAQ:MRUS) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) pulls back 3.7% this week, but still delivers shareholders stellar 31% CAGR over 5 years - Simply Wall St
Logos Global Management LP Invests $50.29 Million in Merus (NASDAQ:MRUS) - Defense World
Market Resilience: Moderna Inc (MRNA) Finishes Weak at 64.14, Down -2.36 - The Dwinnex
Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA) - Defense World
What the Options Market Tells Us About Micron Technology - Benzinga
Micron Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Market Recap: MaxLinear Inc (MXL)’s Positive Momentum, Closing at 14.31 - The Dwinnex
XTX Topco Ltd Sells 1,569 Shares of Micron Technology, Inc. (NASDAQ:MU) - Defense World
Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Pacer Advisors Inc. - Defense World
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):